Scholar Rock (NASDAQ: SRRK; the “Company”), today announced that the company granted inducement equity awards covering an aggregate of 7,800 shares of its common stock to two newly hired employees,...
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and...
Completed constructive and collaborative in-person Type A meeting with U.S. Food and Drug Administration (FDA) on November 12 th for apitegromab biologics license application (BLA)...
Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the company granted inducement equity awards covering an aggregate of 30,000 shares of its common stock to 1 newly hired employee, consisting...
These firms present at least a modest risk/reward profile, but could be preparing for a share price turnaround depending upon how earnings season plays out.
Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and...
Scholar Rock (NASDAQ: SRRK) today announced that it will report third quarter 2025 financial results on Friday, November 14, 2025, before the financial markets open. Following the release...
Scholar Rock (NASDAQ: SRRK; the “Company”), a late-stage biopharmaceutical company focused on developing and commercializing apitegromab for children and adults with spinal muscular atrophy (SMA) and...
Truist Financial analyst Srikripa Devarakonda reiterated a Buy rating on Scholar Rock Holding today. The company’s shares closed yesterday at $34.28.Elevate Your Investing Strategy: Take advantage of...
Piper Sandler analyst Allison Bratzel maintained a Buy rating on Scholar Rock Holding today and set a price target of $51.00. The company’s shares closed yesterday at $34.28.Elevate Your Investing Strategy:...